Aptis Expands ADC Platform Through Strategic Partnerships for Next-Generation Cancer Therapeutics
核心洞察
Aptis (搜索) signed agreements with Kops Bio (搜索) for degrader-antibody conjugate (搜索) (DAC) development and J2H Biotech (搜索) for antibody-drug conjugate (ADC) development, leveraging its AbClick® conjugation platform.
The Kops Bio (搜索) partnership focuses on developing DACs that eliminate target proteins (搜索) rather than inducing cell death, representing a shift from conventional ADC mechanisms.
Both collaborations aim to create first-in-class cancer (搜索) therapeutics by combining Aptis (搜索)'s site-selective linker technology with partners' specialized payload platforms.
Aptis (搜索) has announced two strategic partnerships that position the company at the forefront of next-generation cancer (搜索) therapeutics development. The biotech firm signed agreements with Kops Bio (搜索) for degrader-antibody conjugate (搜索) (DAC) development and J2H Biotech (搜索) for antibody-drug conjugate (ADC) advancement, both leveraging Aptis's proprietary AbClick® conjugation platform.
Pioneering DAC Development with Kops Bio
On November 26, Aptis (搜索) and Kops Bio (搜索) announced a business agreement for joint research on next-generation DAC therapeutics. This collaboration combines Aptis's third-generation site-selective linker conjugation platform with Kops Bio's expertise in covalent inhibitors and molecular glue degraders.
DACs represent a significant advancement over conventional ADCs by eliminating target proteins (搜索) rather than simply inducing cell death. Kops Bio (搜索) brings its proprietary chemoproteomics platform, RaPIDome, which enables the discovery of new targets and design of degradation mechanisms.
"We are very pleased to collaborate with Kops Bio (搜索), which possesses unique technological capabilities in the field of protein degrader new drugs," said Han Taedong, CEO of Aptis (搜索). "Aptis, which has been recognized for its technological competitiveness in the global ADC market, will do its utmost to accelerate the establishment of a world-class DAC pipeline through this partnership."
The companies plan to jointly develop DAC candidates for treating both solid and hematologic cancers (搜索), marking a notable shift from conventional therapeutic approaches.
ADC Innovation Through J2H Biotech Partnership
In October, Aptis (搜索) signed a memorandum of understanding with J2H Biotech (搜索) for developing a first-in-class ADC novel drug candidate. This partnership combines Aptis's AbClick® technology with J2H Biotech's OPTIFLEX® payload platform to create next-generation anticancer drugs with global competitiveness.
Under this collaboration, J2H Biotech (搜索) will design and synthesize highly potent cytotoxic payloads using the OPTIFLEX® platform, while Aptis (搜索) will precisely conjugate these payloads to antibodies to achieve optimal Drug-to-Antibody Ratio (DAR). The development process includes selective cytotoxicity assessments at the cellular level, efficacy and pharmacokinetics verification in tumor xenograft mouse models, and ultimate selection of a preclinical ADC candidate.
"AbClick® technology is our proprietary platform that enables efficient payload conjugation without altering the antibody structure," explained Han Taedong. "Through this collaboration, we expect to develop a next-generation ADC drug that maximizes both selectivity and potency."
Technology Platform Advantages
Aptis (搜索)'s AbClick® platform represents a third-generation site-selective linker conjugation technology that enables precise conjugation of degrader drugs to antibodies. This technology allows for efficient payload conjugation without altering antibody structure, a critical advantage in maintaining therapeutic efficacy.
Kim Jaeseon, CEO of J2H Biotech (搜索), emphasized the strategic value of the partnership: "Combining the precise chemical design capabilities of the OPTIFLEX® platform with Aptis (搜索)'s conjugation technology will enable the creation of a globally competitive first-in-class ADC candidate."
Market Positioning and Future Outlook
Both partnerships demonstrate the growing capabilities of domestic biotech companies in establishing competitive positions in the global precision anticancer drug market. ADCs represent a rapidly expanding field where global pharmaceutical companies are actively focusing development efforts, making these collaborations particularly significant for market entry.
Choi Hwangun, CEO of Kops Bio (搜索), highlighted the therapeutic potential: "Aptis (搜索), with its third-generation site-selective linker conjugation platform, is the ideal partner in the DAC field, which has the potential to overcome the limitations of existing anticancer drugs. By combining Kops Bio's expertise in targeted protein degradation with Aptis's proven linker technology, we aim to accelerate the development of 'First-in-Class' new drugs that can provide new treatment options for patients suffering from intractable cancers."
The companies plan to strengthen their ADC and DAC drug development capabilities through these proprietary domestic platforms, with sequential progression through preclinical research, clinical entry, and global technology transfer for derived candidates.